<DOC>
	<DOCNO>NCT02206932</DOCNO>
	<brief_summary>This study safety effectiveness hepatitis C medication sofosbuvir simeprevir patient HIV hepatitis C ( HCV ) virus .</brief_summary>
	<brief_title>A Study Safety Effectiveness Simeprevir Sofosbuvir Patients With HIV Hepatitis C</brief_title>
	<detailed_description>This research study investigational combination two hepatitis C medication call sofosbuvir ( SOF ) simeprevir ( SMV ) . Both medication approve U.S. Food Drug Administration ( FDA ) treatment hepatitis C combination medication . The combination sofosbuvir simeprevir approve FDA test investigational combination research study . The purpose study see SOF + SMV give 12 week safe able clear Hepatitis C virus ( HCV ) subject co-infected HIV-1 scarring liver ( fibrosis 3 4 scale 0-4 , 4 scarring , also know cirrhosis ) . This study investigator-initiated clinical trial sponsor University California , San Francisco ( UCSF ) , support study drug simeprevir provide Janssen Scientific Affairs , LLC .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Willing able provide write informed consent Male female , age ≥ 18 year Body mass index ( BMI ) ≥ 18 kg/m2 HCV RNA ≥ 104 IU/mL Screening HCV genotype 1 screen prior documentation . Any nondefinitive genotype result exclude subject study participation Chronic HCV infection ( ≥ 6 month ) document prior medical history liver biopsy Fibrosis determination : Fibrosis Metavir F3/F4 may establish one following : 1 . Liver biopsy point time Metavir score F3/F4 , equivalent alternative scale . 2 . Fibroscan ≥ 9.5 kPA 3 . FibroSURE : ≥ 0.58 Liver imaging within 12 month prior Baseline/Day 1 required subject know cirrhosis exclude hepatocellular carcinoma ( HCC ) . Acceptable liver image include ultrasound , CT scan MRI . HCV treatment status one following : 1 . HCV TreatmentNaive : No prior exposure IFN , RBV , approve experimental HCVspecific DAA agents 2 . HCV TreatmentExperienced : Virologic failure treatment PEGIFN+RBVor standard IFN +RBV . Prior exposure HCV polymerase protease inhibitor exclusionary . Prior treatment experience patient categorized one following : i. HCV TreatmentIntolerant : Subjects discontinue HCV treatment due development significant worsen treatment related adverse event ii . Null responder : HCV RNA &lt; 2 log10 decline first 12 week treatment iii . Partial responder : HCV RNA ≥ 2 log10 decline first 12 week treatment stop therapy due inadequate virologic response iv . Relapse : Undetectable HCV RNA ( HCV RNA &lt; LLOQ ) treatment , experience breakthrough relapse HIV1 infection document HIV1 antibody screening time prior screen HIV treatment status : For subject receive ART , HIV RNA must &lt; 40 copies/ml screen &lt; 200 copies/ml least 12 week prior screen . Changes therapy 12 week prior enrollment permit long due HIV treatment failure . HIV ART allow study follow administer per prescribe information package insert : NRTIs : emtricitabine , lamivudine , tenofovir , abacavir Maraviroc Integrase inhibitor : dolutegravir raltegravir NNRTI 's : rilpivirine Enfuvitide Fixed dose combination permit . Screening ECG without clinically significant abnormality Subjects must follow laboratory parameter Screening Preentry ( preentry visit require ) : CD4 Tcell count &gt; 100 cells/mm3 ART , ≥ 350 cells/mm3 ART ALT ≤10 x upper limit normal ( ULN ) AST ≤10 x ULN Direct bilirubin ≤1.5 ULN Creatinine clearance ( CrClr ) ≥50 mL /min , calculate CockcroftGault equation Hemoglobin ≥10 g/dL Albumin ≥3g/dL INR ≤ 1.5 x ULN unless subject know hemophilia stable anticoagulant regimen affect INR Alpha feto protein ( AFP ) level &lt; 50 . If ≥ 50 , liver image study ( eg , ultrasound , CT scan , MRI ) show evidence hepatocellular carcinoma within 3 month study enrollment Female subject reproductive potential ( defined woman postmenopausal least 24 consecutive month , ie , menses within precede 24 month , woman undergo surgical sterilization , specifically hysterectomy and/or bilateral oophorectomy bilateral salpingectomy ) must negative serum pregnancy test sensitivity least 25 mIU/mL perform screening , within 48 hour prior study entry . All subject must agree participate conception process ( eg , active attempt become pregnant impregnate , sperm donation , vitro fertilization ) . NOTE : Female candidate pregnant breastfeed eligible . A male candidate pregnant female partner eligible study . When participate sexual activity could lead pregnancy , subject must agree use least two nonhormonal form contraceptive simultaneously receive protocolspecified medication , 4 week stop medication . Such method include : Condoms ( male female ) without spermicidal agent Diaphragm cervical cap spermicide Intrauterine device ( IUD ) Tubal ligation NOTE : Providers subject advise contraceptive choice list prevent HIV transmission may actually increase risk HIV acquisition . Study subject sexually active HIV1 negative unknown HIV1 serostatus partner advise need consider effective strategy reduce risk HIV transmission , well meet requirement effective contraception participation study . Study subject discuss contraceptive choice HIV risk reduction method health care provider . Subjects reproductive potential ( woman postmenopausal least 24 consecutive month undergone hysterectomy and/or bilateral oophorectomy salpingectomy men document azoospermia undergone vasectomy ) eligible without require use contraceptive . Acceptable documentation sterilization menopause specify . Written oral documentation communicate clinician clinician 's staff one following : Physician report/letter Operative report source documentation patient record ( laboratory report azoospermia require document successful vasectomy ) Discharge summary Follicle stimulate hormonerelease factor ( FSH ) measurement elevate menopausal range establish report laboratory . Subject must able comply dose instruction study drug administration able complete study schedule assessment . Hepatic decompensation point time ( include variceal bleeding , hepatic encephalopathy , ascites ) HBs Ag + Prior HCV treatment HCV protease inhibitor HCV polymerase inhibitor include sofosbuvir Other know cause significant liver disease include chronic acute hepatitis B , acute hepatitis A , hemochromatosis , homozygote alpha1 antitrypsin deficiency . Serious illness include malignancy within 24 week prior study entry , chronic medical condition opinion site investigator may preclude completion protocol . Presence active acute AIDSdefining opportunistic infection within 12 week prior study entry . Use prohibit concomitant medication ChildPugh Score 6.2.2 Preentry &gt; 6</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HIV</keyword>
	<keyword>Simeprevir</keyword>
	<keyword>Sofosbuvir</keyword>
</DOC>